0.0 - 4.0 ng/mL
PSA testing is performed by ECLIA on the Roche Cobas 8000. The PSA assay is intended to be used as an aid in the detection of prostate cancer and as an aid in the management (monitoring) of patients with prostate cancer in accordance with current clinical practice guidelines. These guidelines define biochemical recurrence of prostate cancer as a detectable or rising PSA value post-radical prostatectomy that is >0.2 ng/mL with a second confirmatory level of >0.2 ng/mL.